https://www.selleckchem.com/products/sgc-0946.html
BACKGROUND While epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert a breakthrough effect, the incidence of skin disorders as a side effect has significantly reduced patients' quality of life. This study aimed to develop a treatment for inflammatory ulcers as one of the side effects of afatinib (Giotrif®), a second-generation EGFR-TKI, and established a skin disorder mouse model to investigate the protective effect of minocycline. METHODS First, under inhalation anesthesia with isoflurane, the back of a mal
Like
Comment
Share
